Open access · OA
via OpenAlex
Lysosomal Storage Diseases: From Pathophysiology to Therapy
Giancarlo Parenti, Generoso Andria, Andrea Ballabio
Annual Review of Medicine · 2015 · ▲ 409 citations
Abstract
Lysosomal storage diseases are a group of rare, inborn, metabolic errors characterized by deficiencies in normal lysosomal function and by intralysosomal accumulation of undegraded substrates. The past 25 years have been characterized by remarkable progress in the treatment of these diseases and by the development of multiple therapeutic approaches. These approaches include strategies aimed at increasing the residual activity of a missing enzyme (enzyme replacement therapy, hematopoietic stem cell transplantation, pharmacological chaperone therapy and gene therapy) and approaches based on reducing the flux of substrates to lysosomes. As knowledge has improved about the pathophysiology of lysosomal storage diseases, novel targets for therapy have been identified, and innovative treatment approaches are being developed.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1146/annurev-med-122313-085916
- Canonical
- link ↗
- Fetched
- 2026-06-03 MST
Cite this
APA
Parenti, G., Andria, G., & Ballabio, A. (2015). Lysosomal Storage Diseases: From Pathophysiology to Therapy. <em>Annual Review of Medicine</em>. https://doi.org/10.1146/annurev-med-122313-085916
Vancouver
Parenti G, Andria G, Ballabio A. Lysosomal Storage Diseases: From Pathophysiology to Therapy. Annual Review of Medicine. 2015. doi:10.1146/annurev-med-122313-085916.
BibTeX
@article{giancarlo2015Lysoso,
title = {Lysosomal Storage Diseases: From Pathophysiology to Therapy},
author = {Giancarlo Parenti and Generoso Andria and Andrea Ballabio},
journal = {Annual Review of Medicine},
year = {2015},
doi = {10.1146/annurev-med-122313-085916},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging 2016
Open access · CC-BY
The role of hydrogen sulfide in aging and age-related pathologies
Biotechnology & Biotechnological Equipment 2011
Open access · OA
Measuring Telomere Length—From Ends to Means
Redox Report 2023
Open access · OA
Integrated approach to reducing polypharmacy in older people: exploring the role of oxidative stress and antioxidant potential therapy
Journal of Cellular and Molecular Medicine 2011
Preprint · OA
Pharmaceutical regulation of telomerase and its clinical potential
Molecules (Basel, Switzerland) 2025
Open access · OA
From Elixirs to Geroscience: A Historical and Molecular Perspective on Anti-Aging Medicine.
Cellular and Molecular Life Sciences 2018
Open access · CC-BY